Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 74, Issue 1, 2005, Pages 582-588

  Mandelin, Jami ^a,b,c   Liljeström, Mikko ^a,b   Li, Tian Fang ^a   Ainola, Mari ^a,c   Hukkanen, Mika ^a,c   Salo, Jari ^b   Santavirta, Seppo ^b   Konttinen, Yrjö T ^b,c,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^d Hospital for Joint Replacement   (Finland)

Author keywords

Bone; Cell culture; Loosening; Total joint replacement

Indexed keywords

BLOOD; BONE; CELLS; IMPLANTS (SURGICAL); PATIENT MONITORING; RNA; TISSUE;

LIGANDS; OSTEOPROTEGERIN; PSEUDOSYNOVIAL FLUIDS; WESTERN BLOT ANALYSIS;

JOINT PROSTHESES;

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCITONIN RECEPTOR; CATHEPSIN K; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ACIDITY; ARTICLE; BONE MATRIX; CELL CULTURE; FIBROBLAST; FOREIGN BODY; GENE EXPRESSION; GIANT CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTINUCLEAR CELL; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOLYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTHESIS LOOSENING; PROTEIN EXPRESSION; SYNOVIAL FLUID; SYNOVIUM; TOTAL HIP PROSTHESIS; WESTERN BLOTTING;

ACID PHOSPHATASE; ANALYSIS OF VARIANCE; ARTHROPLASTY, REPLACEMENT, HIP; BLOTTING, WESTERN; BONE RESORPTION; CARRIER PROTEINS; CATHEPSINS; CELL NUCLEUS; FIBROBLASTS; GLYCOPROTEINS; HUMANS; ISOENZYMES; LEUKOCYTES, MONONUCLEAR; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MONOCYTES; OSTEOCLASTS; OSTEOPROTEGERIN; PHENOTYPE; PROSTHESIS FAILURE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CALCITONIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNOVIAL FLUID; SYNOVIAL MEMBRANE; TIME FACTORS;

EID: 21444446820     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbm.b.30244     Document Type: Article

References (35)

1. Goldring SR, Jasty M, Roelke MS, Rourke CM, Bringhurst FR, Harris WH. Formation of a synovial-like membrane at the bone-cement interface. Its role in bone resorption and implant loosening after total hip replacement. Arthritis Rheum 1986;29: 836-842.
2. Murray DW, Rushton N. Macrophages stimulate bone resorption when they phagocytose particles. J Bone Joint Surg Br 1990;72:988-992.
3. Kadoya Y, Kobayashi A, Ohashi H. Wear and osteolysis in total joint replacements. Acta Orthop Scand Suppl 1998;278:1-16.
4. Konttinen YT, Xu J-W, Patiala H, Imai S, Waris V, Li T-F, Goodman SB, Nordsletten L, Santavirta S. Cytokines in aseptic loosening of total hip replacement. Curr Orthop 1997;11:40-47.
5. Takagi M. Neutral proteinases and their inhibitors in the loosening of total hip prostheses. Acta Orthop Scand Suppl 1996; 271:3-29.
6. Konttinen YT, Takagi M, Mandelin J, Lassus J, Salo J, Ainola M, Li TF, Virtanen I, Liljestrom M, Sakai H, Kobayashi Y, Sorsa T, Lappalainen R, Demulder A, Santavirta S. Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis. J Bone Miner Res 2001;16:1780-1786.
7. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
8. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
9. Quinn JM, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424-4427.
10. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
11. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-1337.
12. Vignery A. Osteoclasts and giant cells: macrophage-macrophage fusion mechanism. Int J Exp Pathol 2000;81:291-304.
13. Boissy P, Destaing O, Jurdic P. RANKL induces formation of avian osteoclasts from macrophages but not from macrophage polykaryons. Biochem Biophys Res Commun 2001;288:340-346.
14. Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 2004;25:565-573.
15. Mandelin J, Li T-F, Liljestrom M, Kroon ME, Hanemaaijer R, Santavirta S, Konttinen YT. Imbalance of RANKL/RANK/ OPG system in interface tissue in loosening of total hip replacement (THR) implants. J Bone Joint Surg Br 2003;85:1196-1201.
16. Itonaga I, Sabokbar A, Murray DW, Athanasou NA. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. Ann Rheum Dis 2000;59:26-31.
17. Mandelin J, Li T-F, Hukkanen M, Liljestrom M, Salo J, Santavirta S, Konttinen YT. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of NF-kappaB ligand, osteoprotegrin and cathepsin K. J Rheumatol. In press.
18. Haynes DR, Crotti TN, Potter AE, Loric M, Atkins GJ, Howie DW, Findlay DM. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br 2001;83:902-911.
19. Sabokbar A, Fujikawa Y, Neale S, Murray DW, Athanasou NA. Human arthroplasty derived macrophages differentiate into osteoclastic bone resorbing cells. Ann Rheum Dis 1997;56:414-420.
20. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-994.
21. Takagi M, Santavirta S, Ida H, Ishii M, Takei I, Niissalo S, Ogino T, Konttinen YT. High-turnover periprosthetic bone remodeling and immature bone formation around loose cemented total hip joints. J Bone Miner Res 2001;16:79-88.
22. Santavirta S, Konttinen YT, Bergroth V, Eskola A, Tallroth K, Lindholm TS. Aggressive granulomatous lesions associated with hip arthroplasty. Immunopathological studies. J Bone Joint Surg Am 1990;72:252-258.
23. Santavirta S, Konttinen YT, Hoikka V, Eskola A. Immunopathological response to loose cementless acetabular components. J Bone Joint Surg Br 1991;73:38-42.
24. Jasty MJ, Floyd WE III, Schiller AL, Goldring SR, Harris WH. Localized osteolysis in stable, non-septic total hip replacement. J Bone Joint Surg Am 1986;68:912-919.
25. Schmalzried TP, Jasty M, Harris WH. Periprosthetic bone loss in total hip arthroplasty. Polyethylene wear debris and the concept of the effective joint space. J Bone Joint Surg Am 1992;74:849-863.
26. Robertsson O, Wingstrand H, Kesteris U, Jonsson K, Onnerfalt R. Intracapsular pressure and loosening of hip prostheses. Preoperative measurements in 18 hips. Acta Orthop Scand 1997; 68:231-234.
27. Takei I, Takagi M, Ida H, Ogino T, Santavirta S, Konttinen YT. High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints. J Rheumatol 2000;27:894-899.
28. Santavirta S, Hoikka V, Eskola A, Konttinen YT, Paavilainen T, Tallroth K. Aggressive granulomatous lesions in cementless total hip arthroplasty. J Bone Joint Surg Br 1990;72:980-984.
29. Jiranek WA, Machado M, Jasty M, Jevsevar D, Wolfe HJ, Goldring SR, Goldberg MJ, Harris WH. Production of cytokines around loosened cemented acetabular components. Analysis with immunohistochemical techniques and in situ hybridization. J Bone Joint Surg Am 1993;75:863-879.
30. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236-1238.
31. Xu JW, Konttinen YT, Waris V, Patiala H, Sorsa T, Santavirta S. Macrophage-colony stimulating factor (M-CSF) is increased in the synovial-like membrane of the periprosthetic tissues in the aseptic loosening of total hip replacement (THR). Clin Rheumatol 1997;16:243-248.
32. Nivbrant B, Karlsson K, Karrholm J. Cytokine levels in synovial fluid from hips with well-functioning or loose prostheses. J Bone Joint Surg Br 1999;81:163-166.
33. Kim KJ, Kotake S, Udagawa N, Ida H, Ishii M, Takei I, Kubo T, Takagi M. Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. J Biomed Mater Res 2001;58:393-400.
34. Ulrich-Vinther M, Carmody EE, Goater JJ, Soballe S, O'Keefe RJ, Schwarz EM. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg Am 2002;84:1405-1412.
35. Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 2002; 17:192-199.